<DOC>
	<DOCNO>NCT00242762</DOCNO>
	<brief_summary>The primary objective study evaluate activity combination ZD1839 , docetaxel cisplatin subject recurrent and/or metastatic head neck cancer estimate objective response rate ( complete response [ CR ] partial response [ PR ] ) study closure .</brief_summary>
	<brief_title>ZD1839 ( IRESSAâ„¢ ) Combination With Docetaxel &amp; Cisplatin Subjects With Metastatic Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Male female , age 18 70 year , inclusive 2 . Histologically cytologicallyconfirmed recurrent and/or metastatic SCCHN 3 . Primary tumour site oral cavity , oropharynx , hypopharynx larynx 4 . At least one unidimensionally measurable lesion accord RECIST 5 . World Health Organisation ( WHO ) performance status ( PS ) 0 1 6 . No previous chemotherapy recurrent metastatic disease 7 . Before subject registration quality life questionnaire complete 1 . Previous chemotherapy recurrent metastatic disease 2 . Less 6 month since prior induction adjuvant platinum and/or taxanes chemotherapy 3 . Known severe hypersensitivity ZD1839 excipients product 4 . Known , severe hypersensitivity docetaxel cisplatin excipients product , drug formulate polysorbate 80 5 . Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ 6 . Any unresolved chronic toxicity great common toxicity criterion ( CTC ) grade 2 previous anticancer therapy ( except alopecia ) 7 . Absolute neutrophil count ( ANC ) less 1.5 x109/litre ( L ) , platelets less 100 x 109/L haemoglobin less 10 g/dl 8 . Serum bilirubin great upper limit reference range ( ULRR ) 9 . Serum creatinine great 1.5 mg/dl despite adequate rehydration 10 . Creatinine clearance le 60 ml/min assess 24 hour urine collection 11 . As judged investigator , evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) 12 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 1.5 time ULRR alkaline phosphatase ( ALP ) great 2.5 time ULRR 13 . Evidence significant clinical disorder laboratory find make undesirable subject participate study 14 . Pregnancy breast feeding ( woman childbearing potential ) 15 . Concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , St John 's Wort 16 . Treatment nonapproved investigational drug within 30 day Day 1 study treatment 17 . Any evidence clinically active interstitial lung disease ( patient chronic stable radiographic change asymptomatic need exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Head Neck Neoplasms</keyword>
	<keyword>Cancer Head Neck</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Head Cancer</keyword>
	<keyword>Neck Cancer</keyword>
</DOC>